High-yield expression and purification of recombinant human macrophage migration inhibitory factor.

We have expressed the human macrophage migration inhibitory factor (MIF) in Escherichia coli using the pKP 1500 expression plasmid, which contains the tac promoter and a temperature-sensitive origin of replication, to ensure a high plasmid copy number at elevated temperatures. The recombinant protein accumulated intracellularly in soluble form. We have designed a simple two-step procedure for protein purification by gel filtration on Sephadex G-50 and cation exchange chromatography on CM cellulose columns. This results in significantly improved yields. One gram of recombinant human MIF was isolated from 50 g of E. coli cells (wet weight). The 12.5-kDa protein was shown to be pure by SDS-PAGE, IEF, and HPLC. The identity of the purified protein was verified by N-terminal amino acid sequencing. The purified protein exhibits MIF activity. The near-UV CD and the 1H NMR spectra confirmed its highly ordered, native-like structure. The far-UV CD spectrum revealed that recombinant human MIF contains well-defined secondary structure.

The continuing care client.

In the present contribution, I would like to describe modes of care for people who, because of their mental health problems, need the continuing or occasional help of different institutions (Ramon, 1990). Some service structures are described which are the most outstanding. The history and organisation of relevant institutions, as well as possibilities for the improvement of their work, or alternatively their abolition, are also discussed.

Isolation, partial characterization and complete amino acid sequence of the toxic phospholipase A2 from the venom of the common viper, Vipera berus berus.

A basic, toxic phospholipase A2 was purified from the venom of Vipera berus berus (Vbb) by a single purification step, using hydrophobic chromatography. The primary structure of isolated protein was established from peptides generated by Gly-specific papaya proteinase IV, beta-trypsin, CNBr and mild acid hydrolysis. The enzyme consists of a single chain of 122 amino acid residues with 14 Cys in positions characteristic for the phospholipase A2 subgroup IIA. As far as we know, this is the first complete Vipera berus phospholipase A2 amino acid sequence reported.

Cathepsins B, H and L in human breast carcinoma.

We have measured the activity of the cysteine proteinase cathepsin B, the inhibitory activity of cysteine proteinase inhibitors and the amounts of cathepsins B, H and L in normal sera and sera from patients with breast cancer, as well as in tissue homogenates of tumorous and non-tumorous samples. The amounts of cathepsin B, determined by ELISA in tumour sera (n = 17) were significantly higher than the amounts determined in normal sera (n = 20). On the other hand, the differences in the amounts measured in tumour sera were not significant when compared with the known histopathological characteristics. In cytosols of breast cancer tumour tissue in general, the level of cathepsin H was higher than those of cathepsins B and L in all samples tested. In the same samples, at least a 10-fold increase of cathepsin B (activity and quantity) was detected in matched pairs (n = 20) of carcinoma and normal tissue of the same breast (p less than 0.01). The amount of cathepsin B correlated with the degree of malignancy inside the histological subtypes of invasive ductal carcinoma (n = 90, p less than 0.01). In addition, a negative correlation of values for cathepsin B with the involvement of regional lymph nodes (n = 75, p less than 0.01) was found inside the same group. In contrast, the activities of cysteine proteinase inhibitors did not correlate with any of the known clinical data. Our data provide further indirect evidence for the involvement of cathepsin B in the processes of tumour growth and metastasis in breast carcinoma. The follow-up studies will verify the prognostic value of these findings.

Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.

Synovial fluids and sera of patients with inflammatory and metabolic joint diseases contain different cysteine proteinases. The quantities of cathepsins B and H were determined by newly developed specific enzyme-linked immunoassay tests (ELISA), with detection limits of 0.5 microgram/l for cathepsin B and 3 micrograms/l for cathepsin H. The values of cathepsin B in normal sera ranged from 0.6 microgram/l to 2 micrograms/l, whereas in sera of patients with joint diseases they ranged from 1.7 micrograms/l to 18 micrograms/l. Cathepsin H was not found in sera (values below 3 micrograms/l), but was measurable in patients' synovial fluids. Patients with rheumatoid arthritis have on average the highest values of cathepsin B in synovial fluids, whereas patients with undifferentiated arthritis have the highest values of cathepsin H. The results show that cathepsins B and H are present in arthritic synovial fluids, where they may be implicated in destructive processes. There is yet no clear correlation between the quantity of each cathepsin released in synovia and the clinical diagnosis or the stage of the disease.

Distribution of vipera ammodytes toxic phospholipase A in the cat and its ability to cross the blood-brain barrier.

Several phospholipases A could be isolated from the venom of the European viper, Vipera ammodytes, having different specific activities toward egg lecithin and different lethalities. The most lethal of these enzymes is fraction "k2" having an intravenous LD50 for white mice of 0.021 mg per kg and a specific activity of 280 microM/min mg at 40 degrees C. The enzyme could be labeled with 131I without loosing its enzymatic activity and lethality. The passage of this enzyme from blood into cerebrospinal fluid (CSF) was followed in anesthetized cats. Approximately 1% of the blood level of the enzyme was found in CSF indicating the ability of this protein to penetrate the blood-brain barrier. Although the lethality of fraction "k2" becomes as low as 0.085 microgram/kg when applied intraventricularly, it is not very likely that the central effects of this fraction are of major importance in envenomation since the distribution pattern of the labeled enzyme shows that most of the protein remains in liver, lungs and kidneys, presumably non-selectively bound to membranes and only 0.2% of the injected fraction can reach the brain. Relatively high amount of enzyme was also found in the diaphragm. The penetration of the blood-brain barrier of the radiolabeled phospholipase is within the limits for the proteins of this size (M.w. 14500).